Latest Glycogen storage disease type II Stories
The life of a Minnesota boy suffering with a rare and serious form of the genetic disorder Pompe disease has been extended after treatment with a drug typically used to suppress the immune system of those with cancer and rheumatoid arthritis.
CRANBURY, N.J., Jan. 8 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced the election of Sol J. Barer, Ph.D., to its Board of Directors. Dr. Barer currently serves as Chairman and Chief Executive Officer of Celgene Corporation. As an industry veteran, Dr.
Genzyme Corporation (Nasdaq: GENZ) today announced that its U.S.
CRANBURY, N.J., Aug. 7 /PRNewswire-FirstCall/ -- Amicus Therapeutics , a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, today announced financial results for the second quarter of 2008.
CRANBURY, N.J., Aug.
CRANBURY, N.J., July 31 /PRNewswire-FirstCall/ -- Amicus Therapeutics , a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, will announce second quarter 2008 financial results after the regular close of markets on Thursday, August 7, 2008.
By Lisa Richwine WASHINGTON (Reuters) - The first drug to treat a rare, debilitating muscle disease that can kill infants within a year won U.S. approval on Friday, health officials said. Genzyme Corp.
- The practice of two or more parties jointly purchasing all or part of a butchered cow and dividing the meat between them.